Kathleen McGuinness is an associate in the firm’s Litigation department and is a member of the firm’s Life Sciences Disputes group. She focuses her practice on patent litigation, with an emphasis on biotechnology and pharmaceuticals. She joined Goodwin in 2015.
Kathleen has participated in all phases of patent litigation, including pre-suit analysis, fact and expert discovery, and trial. She has experience litigating patents in multiple areas of technology, including software, electronics, medical devices, and pharmaceuticals.
Kathleen’s recent work includes representing:
- Fresenius Kabi USA in Hatch-Waxman patent litigation in the District of Delaware concerning the drug icatibant (Firazyr®), which is indicated for the treatment of hereditary angioedema. Shire Orphan Therapies LLC et al v. Fresenius Kabi USA, LLC
- Actavis Labs in Hatch-Waxman patent litigation in the District of Delaware concerning budesonide tablets (Uceris®), which is indicated for the treatment of mild to moderate ulcerative colitis. A summary judgment of non-infringement was granted under Rule 52(c). Cosmo Techs. Ltd. & Santarus, Inc. v. Actavis Labs. FL, Inc.
- MSN Laboratories in Hatch-Waxman patent litigation in the District of Delaware concerning the drug riociguat (Adempas®), which is indicated for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Adverio Pharma GmbH, et al. v. MSN Laboratories Pvt. Ltd. et al.
Harvard Law School
Massachusetts Institute of Technology
Recognition & Awards
Kathleen has been recognized by The Best Lawyers in America Ones to Watch for her work in Litigation - Patent 2022.
Kathleen was named to The Best Lawyers in America 2021: Ones to Watch.